CN102340991B - 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物 - Google Patents

向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物 Download PDF

Info

Publication number
CN102340991B
CN102340991B CN201080010150.0A CN201080010150A CN102340991B CN 102340991 B CN102340991 B CN 102340991B CN 201080010150 A CN201080010150 A CN 201080010150A CN 102340991 B CN102340991 B CN 102340991B
Authority
CN
China
Prior art keywords
aqueous solution
peg
purposes
solution
activating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080010150.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102340991A (zh
Inventor
B·P·卡布拉
M·高施
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Alcon Manufacturing Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Manufacturing Ltd filed Critical Alcon Manufacturing Ltd
Publication of CN102340991A publication Critical patent/CN102340991A/zh
Application granted granted Critical
Publication of CN102340991B publication Critical patent/CN102340991B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201080010150.0A 2009-03-03 2010-03-03 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物 Expired - Fee Related CN102340991B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15692209P 2009-03-03 2009-03-03
US61/156,922 2009-03-03
PCT/US2010/026033 WO2010101992A1 (en) 2009-03-03 2010-03-03 Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Publications (2)

Publication Number Publication Date
CN102340991A CN102340991A (zh) 2012-02-01
CN102340991B true CN102340991B (zh) 2014-02-26

Family

ID=42678800

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080010150.0A Expired - Fee Related CN102340991B (zh) 2009-03-03 2010-03-03 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物

Country Status (12)

Country Link
US (2) US20100227905A1 (enExample)
EP (1) EP2403335B1 (enExample)
JP (1) JP5583146B2 (enExample)
KR (2) KR20110130454A (enExample)
CN (1) CN102340991B (enExample)
AU (1) AU2010221369B2 (enExample)
BR (1) BRPI1012302A2 (enExample)
CA (1) CA2753690A1 (enExample)
ES (1) ES2508290T3 (enExample)
MX (1) MX2011008731A (enExample)
WO (1) WO2010101992A1 (enExample)
ZA (1) ZA201105505B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
CN105412094A (zh) 2009-07-06 2016-03-23 爱尔皮奥治疗有限公司 用于防止癌细胞转移的化合物、组合物和方法
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
CN103140215A (zh) * 2010-07-21 2013-06-05 爱尔康研究有限公司 具有提高的溶解度特征的药物组合物
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
US20140160236A1 (en) * 2011-07-29 2014-06-12 The Regents Of The University Of California Lensfree holographic microscopy using wetting films
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
CA2863632C (en) 2012-01-19 2017-07-11 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
JP6138904B2 (ja) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
CN104363924B (zh) 2012-03-16 2018-04-17 约翰霍普金斯大学 用于递送hif‑1抑制剂的控制释放调配物
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2844227B1 (en) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
JP6392209B2 (ja) 2012-05-04 2018-09-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
MX368142B (es) * 2013-04-30 2019-09-20 Intas Pharmaceuticals Ltd Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
WO2015127389A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic enema formulations and methods of use
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
EP3233056B1 (en) 2014-12-15 2023-11-15 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of ocular disorders
EP3250184B1 (en) 2015-01-27 2024-12-18 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
ES2981607T3 (es) 2015-09-23 2024-10-09 Eyepoint Pharmaceuticals Inc Activadores de Tie-2 para uso en el tratamiento de la presión intraocular
BR112018009644A2 (pt) 2015-11-12 2018-11-06 Graybug Vision Inc micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
WO2018175922A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
AU2020264969B2 (en) 2019-04-29 2025-06-05 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
PL4065131T3 (pl) * 2019-11-28 2024-12-16 Caprika Srl Kompozycja do zastosowania doodbytniczego w leczeniu zaparć

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
AU668447B2 (en) * 1993-04-16 1996-05-02 Wakamoto Pharmaceutical Co., Ltd. Reversible, thermally gelling water-base medicinal composition
AU734650B2 (en) * 1996-05-07 2001-06-21 Toray Industries, Inc. Ophthalmic preparations
PL1638941T3 (pl) * 2003-05-22 2010-11-30 Abbvie Bahamas Ltd Indazolowe, benzizoksazolowe i benzizotiazolowe inhibitory kinaz
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
CN101006988A (zh) * 2005-09-26 2007-08-01 刘凤鸣 葛根素的缓释制剂
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070148225A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CN101687042A (zh) * 2007-07-20 2010-03-31 爱尔康公司 用于递送作为受体酪氨酸激酶抑制剂(RTKi)的化合物至眼部的药物制剂

Also Published As

Publication number Publication date
KR20160135372A (ko) 2016-11-25
CN102340991A (zh) 2012-02-01
US20130137741A1 (en) 2013-05-30
MX2011008731A (es) 2011-09-29
BRPI1012302A2 (pt) 2015-09-22
AU2010221369A1 (en) 2011-08-25
KR20110130454A (ko) 2011-12-05
EP2403335B1 (en) 2014-08-20
EP2403335A1 (en) 2012-01-11
JP2012519694A (ja) 2012-08-30
US20100227905A1 (en) 2010-09-09
ZA201105505B (en) 2013-10-30
CA2753690A1 (en) 2010-09-10
ES2508290T3 (es) 2014-10-16
JP5583146B2 (ja) 2014-09-03
EP2403335A4 (en) 2012-08-29
AU2010221369B2 (en) 2014-03-13
WO2010101992A1 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
CN102340991B (zh) 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
JP5583145B2 (ja) レセプターチロシンキナーゼ阻害（ＲＴＫｉ）化合物の眼への送達のための薬学的組成物
JP6965308B2 (ja) 後眼部へ薬物を送達するための眼用製剤
US20070149593A1 (en) PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US8912236B2 (en) Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
US20070149480A1 (en) PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CN101687042A (zh) 用于递送作为受体酪氨酸激酶抑制剂(RTKi)的化合物至眼部的药物制剂
US20070173538A1 (en) PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20110200662A1 (en) Method For The Treatment Of Proliferative Disorders Of The Eye
KR102474404B1 (ko) 다중 표적 억제제의 현탁액 조성물
Bakri et al. Antiangiogenic agents: intravitreal injection
TW202038928A (zh) 多目標抑製劑的懸浮液組合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140226

Termination date: 20170303